A Study of Olaparib and Durvalumab in Prostate Cancer

Part of paid clinical trials in Duarte, California.

Sponsor
Memorial Sloan Kettering Cancer Center
Study ID
NCT03810105
Phase
PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
MALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Olaparib — DRUG
    Olaparib 300mg twice daily (600mg total daily dose)
  • Durvalumab — DRUG
    Durvalumab 1500mg IV monthly

Study Details

The purpose of this study is to determine if the combination of olaparib and durvalumab are better than the standard of care for treating prostate cancer.

Key Dates

Start date
Mar 7, 2019
Status verified
Feb 2024
Primary completion
Jul 6, 2023
Completion
Jul 6, 2023

Study Design

Enrollment
5 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Castration Sensitive Biochemically Recurrent Prostate Cancer
    Castration Sensitive Biochemically Recurrent Non-Metastatic Prostate Cancer

Primary Outcome Measure

Therapeutic Efficacy as Defined by Number of Participants With an Undetectable PSA [ Time Frame: 1 year ]

Locations (8)

FacilityCityStateZIPSite coordinators
City of Hope Comprehensive Cancer CenterDuarteCalifornia91010-
University of Illinois at ChicagoChicagoIllinois60637-
Karmanos Cancer InstituteDetroitMichigan48201-
Memorial Sloan Kettering Basking RidgeBasking RidgeNew Jersey07920-
Memorial Sloan Kettering BergenMontvaleNew Jersey07645-
Memorial Sloan Kettering CommackCommackNew York11725-
Memorial Sloan Kettering WestchesterHarrisonNew York10604-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-

Find similar trials in Duarte, CA

By condition

Related Studies